Avtor/Urednik		Šeruga, Boštjan
Naslov		Zdravljenje raka požiralnika s preoperativno kemoradioterapijo
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Medicinska fakulteta
Leto izdaje		2004
Obseg		str. 39
Jezik		slo
Abstrakt		Despite improvements in surgical treatment of esophageal cancer a long-term survival of patients with esophageal cancer is low, especially of patients with locally advanced cancer. In attempt to improve the results of surgery, preoperative and postoperative treatment with chemotherapy, radiotherapy or combination of both has been used. Preoperative chemoradiotherapy seems to be beneficial, mostly in patients who achieve complete pathologic response after chemoradiotherapy. In our retrospective overview the efficiency and toxicity of preoperative chemoradiotherapy in patients with locally advanced esophageal cancer was analysed as well as the influence of pathologic complete response on survival. From 1996 to 2002 we have treated 41 patients with locoregional confined esophageal carcinoma with preoperative chemoradiotherapy (cisplatin 75 mg/m2 on day 1, 22; 5-FU 1000 mg/m2 on days 1-4, 22-25 and concurrent radiotherapy 4500 cGy, 200-300cGy/day; esophagectomy followed 4-S weeks efter radiotherapy) at the Institute of Oncology and Department of Thoracic Surgery in Ljubljana, Slovenia. After surgery patients were followedup regularly at 3-6 months intervals. Pathologic complete response was achieved in 26,8% of the patients. Median overall survival time was 18 months, for patients with achieved pathologic complete response 21,2 months and for patients without it 16 months. The difference is not statistical significant. Postoperative mortality rate was 22% and all patients died of septic shock. Median dose intensity for cisplatin was satisfactory (92,8% of planned dose intensity) and for S-FU unsatisfactory low (71,5% of planned dose intensity). Disease recurred most often locoregionally (31,7%), overall recurrence rate was 43,9%. In comparison with data in the literature our results are in the middle-range and postoperative mortality rate is high. (Abstract truncated at 2000 characters).
Deskriptorji		ESOPHAGEAL NEOPLASMS NEOPLASM STAGING TREATMENT OUTCOME SURVIVAL ANALYSIS RETROSPECTIVE STUDIES